# Newsietter

Compiled by Dr Angela Munoko

# What is Fibrin D-dimer?

D dimer has been in use for almost three decades, as a screening tool for Venous thromboembolism (VTE)<sup>1</sup>. It is one of many Fibrin degradation products (FDP) produced after a clot is degraded by the process of fibrinolysis. FDPs come in a variety of molecular weights. However, unlike other FDPs that are formed following degradation of fibrinogen and fibrin, D – dimer is produced exclusively from cross-linked fibrin. D dimer is therefore indicative of clot degradation and not non-specific fibrinolysis<sup>2</sup>.

# Utility

Only a small amount of cross-linked Fibrin is required to generate D-dimer, making it a sensitive marker for VTE<sup>3</sup>. It is therefore a good screening test in individuals at risk of VTE or in individuals with clinical presentation suggestive of the VTE<sup>3</sup>. D dimer should never be used as a standalone test but in conjunction with Clinical pre-test probability and definitive imaging to make the diagnosis of VTE.

In individuals with low clinical pre-test probability assessment, D dimer has high negative predictive value for VTE making it an excellent rule-out test<sup>4,5</sup>.

In contrast, a high D-dimer level, is non-specific to VTE and clinical pretest probability is required to determine the significance of a positive result<sup>4,5</sup>. D dimer values also rise with age and higher cut

# **Causes of high D dimer**

#### Thromboembolism

- a. Arterial such as Myocardial infarction, Stroke, Acute limb ischemia etc
- b. Venous such as Deep venous thrombosis, Pulmonary embolism
- c. Disseminated intravascular coagulation (DIC)

#### Inflammation

a. Infections such as COVID-19

b. Sepsis

# Surgery and trauma

### Liver disease

### **Kidney disease**

#### Vascular disease

a. Vaso-occlusive Sickle cell crisis b. Vascular malformations

#### Malignancy

#### Thrombolytic therapy

#### Pregnancy

- a. Physiological changes
- b. Preeclampsia and Eclampsia



# Clinical indications for D-dimer test<sup>4</sup>:

1) Deep venous thrombosis

is based on In-hospital protocols.

2) Pulmonary thromboembolism

VTE, and definitive imaging is indicated<sup>4</sup>.

- 3) Primary hyperfibrinolysis
- 4) Disseminated intravascular hemolysis
- 5) Prognostic assessment if COVID-19

# **Reference range**

The reference range for D dimer is < 500 ng/mL or 0.5 ug/ml

offs have been proposed for older individuals, though these have yet

to be established<sup>5</sup>. A positive D dimer test is therefore not diagnostic

of VTE but indicates the need for further evaluation. In patients in with

a high pre-test probability, a normal D-dimer level does not exclude

To establish Clinical pre-test probability, clinical assessment may be supplemented / standardized by validated scoring systems<sup>4</sup>. These

scoring systems include Wells, Modified Wells Modified Geneva, and PERC (Pulmonary embolism rule out criteria)<sup>4,5</sup>. Wells scoring system is

the most widely used, however selection of which scoring system to use

PATHOLOGISTS ANCET

# Sample type

#### Heparin whole blood

#### References

- Tripodi A. (2011). D-dimer testing in laboratory practice. Clinical chemistry, 57(9), 1256-1262. https://doi.org/10.1373/clinchem.2011.166249
- Gaffney P.J. (1993). History of the discovery, characterisation and utility of this and other fibrin fragments. Fibrinolysis, 7(0268 – 9499), 2-8.
- https://doi.org/10.1016/0268-9499(93)90039-X
- Adam, S. S., Key, N. S., & Greenberg, C. S. (2009). D-dimer antigen: current concepts and future prospects. Blood, 113(13), 2878–2887. https://doi.org/10.1182/blood-2008-06-165845 Zehnder, JL. (2021). Clinical use of coaaulation tests. UptoDate, Available from
- https://www.uptodate.com/contents/clinical-use-of-coagulation-tests?search=D%20dimer%20high&source=search\_result&selectedTitle=1~150&usage\_typ e=default&display\_rank=1
- Ageno, W. Squizzato, A. Wells, P.S., Buller H.R., Johnson. G. (2013). The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. Thrombosis and Haemostasis, 11(8), 1587 – 1602. https://doi.org/10.1111/ith.12301

5th Avenue Office Suites Opp. Traffic HQ - Upper Hill 5th Ngong Avenue | Ngong Road Tel: 0703 061 000 Email: info@lancet.co.ke www.cerbalancetafrica.ke